Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 12, 2022 | Series A | $350M | 8 | Bain Capital Life Sciences | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bain Capital Life Sciences | Yes | Series A |
Sanofi | — | Series A |
Access Biotechnology | — | Series A |
ARCH Venture Partners | — | Series A |
GV | — | Series A |
Maverick Capital | — | Series A |
Population Health Partners | — | Series A |
Saturn Partners | — | Series A |